Rituximab as monotherapy for the treatment of chronic active antibody-mediated rejection after kidney transplantation.

Détails

Ressource 1Télécharger: 29328536_post_print_cover.pdf (782.86 [Ko])
Etat: Public
Version: Author's accepted manuscript
ID Serval
serval:BIB_C54B7A2AC6FE
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Rituximab as monotherapy for the treatment of chronic active antibody-mediated rejection after kidney transplantation.
Périodique
Transplant international
Auteur(s)
Muller Y.D., Ghaleb N., Rotman S., Vionnet J., Halfon M., Catana E., Golshayan D., Venetz J.P., Aubert V., Pascual M.
ISSN
1432-2277 (Electronic)
ISSN-L
0934-0874
Statut éditorial
Publié
Date de publication
04/2018
Peer-reviewed
Oui
Volume
31
Numéro
4
Pages
451-455
Langue
anglais
Notes
Publication types: Letter
Publication Status: ppublish
Résumé
Chronic active antibody-mediated rejection (caAMR) is a major cause of allograft loss after kidney transplantation (1). The BANFF 2013 classification redefined caAMR by the presence of donor-specific anti-HLA antibodies (DSA) together with immuno-histopathological evidence for active vascular lesions of the endothelium (C4d deposits, glomerulitis, peritubular capillaritis) as well as evidence of chronic tissue injury (transplant glomerulopathy, peritubular capillary basement membrane multilayering or arterial intimal fibrosis) (2,3). Humoral immunity, detected by the presence of DSA, and B cells are considered pivotal in the development of caAMR. Gosset et al. showed that circulating DSA are responsible for accelerated allograft fibrosis independently of acute AMR (1). This article is protected by copyright. All rights reserved.

Mots-clé
Adult, Female, Graft Rejection/drug therapy, Graft Rejection/immunology, Humans, Immunologic Factors/therapeutic use, Kidney Transplantation/adverse effects, Male, Middle Aged, Retrospective Studies, Rituximab/therapeutic use, Young Adult
Pubmed
Web of science
Open Access
Oui
Création de la notice
16/01/2018 8:41
Dernière modification de la notice
20/08/2019 15:40
Données d'usage